drugset / Trial / NCT05442996
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a phase I clinical study designed to evaluate the safety, tolerability, PK characteristics, and preliminary efficacy of HLX35 in combination with HLX10 in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2023-01-06
- Primary completion
- 2024-04-22
- Completion
- 2025-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX35 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | HLX35 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | HLX35 | Unknown | 1 mg/kg | Intravenous |
| Subject | HLX35 | Unknown | 3 mg/kg | Intravenous |
| Subject | HLX35 | Unknown | 10 mg/kg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 200 mg | Intravenous |